Gemcitabine for the treatment of advanced nonsmall cell lung cancer

Autor Toschi, Luca, Cappuzzo, Federico
Vydáno 2009

Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?

Autor Landi, Lorenza, Cappuzzo, Federico
Vydáno 2012

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

Autor Stasi, Irene, Cappuzzo, Federico
Vydáno 2014

Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer

Autor Landi, Lorenza, Cappuzzo, Federico
Vydáno v Ann Transl Med (2015)

EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMation

Autor Landi, Lorenza, Cappuzzo, Federico
Vydáno v Transl Lung Cancer Res (2012)

Targeting MET in NSCLC: looking for a needle in a haystack

Autor Landi, Lorenza, Cappuzzo, Federico
Vydáno v Transl Lung Cancer Res (2014)

Irreversible EGFR-TKIs: dreaming perfection

Autor Landi, Lorenza, Cappuzzo, Federico
Vydáno v Transl Lung Cancer Res (2013)

Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches

Autor Mazza, Valentina, Cappuzzo, Federico
Vydáno v J Thorac Dis (2016)

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer

Autor Stasi, Irene, Cappuzzo, Federico
Vydáno v Lung Cancer (Auckl) (2014)

Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC

Autor Landi, Lorenza, Cappuzzo, Federico
Vydáno v Transl Lung Cancer Res (2016)

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib

Autor Mazza, Valentina, Cappuzzo, Federico
Vydáno v Appl Clin Genet (2017)

A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay

Autor Landi, Lorenza, Cappuzzo, Federico
Vydáno v J Thorac Dis (2017)

How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease

Autor Landi, Lorenza, Cappuzzo, Federico
Vydáno v Transl Lung Cancer Res (2020)

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer

Autor D’Arcangelo, Manolo, Cappuzzo, Federico
Vydáno 2013

K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value

Autor D'Arcangelo, Manolo, Cappuzzo, Federico
Vydáno v ISRN Mol Biol (2012)

Lung Cancer Update 2017: from the test tube to the bed

Autor Bertolaccini, Luca, Cappuzzo, Federico, Solli, Piergiorgio
Vydáno v Ann Transl Med (2018)

Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung ca...

Autor Romanidou, Ourania, Landi, Lorenza, Cappuzzo, Federico, Califano, Raffaele
Vydáno v Ther Adv Med Oncol (2016)

Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR...

Autor Osarogiagbon, Raymond U., Cappuzzo, Federico, Ciuleanu, Tudor, Leon, Larry, Klughammer, Barbara
Vydáno v Transl Lung Cancer Res (2015)

MET overexpression and gene amplification in NSCLC: a clinical perspective

Autor Landi, Lorenza, Minuti, Gabriele, D’Incecco, Armida, Salvini, Jessica, Cappuzzo, Federico
Vydáno v Lung Cancer (Auckl) (2013)

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Autor Drilon, Alexander, Cappuzzo, Federico, Ou, Sai-Hong Ignatius, Camidge, D. Ross
Vydáno v J Thorac Oncol (2016)